Addressing the need to regulate and not simply inhibit pathological angiogenic events in NV-AMD [112], therapeutic modulation of vitronectin and PAI-1 protein expression, either through genetic or pharmacological approaches, could contribute to the restoration of vascular homeostasis and, thus, help to prevent or treat vascular abnormalities in late stage AMD. Here, SERPINE1 is linked to age-related macular degeneration.